ROCHE HOLDING AG

Recent news

• Morgan Stanley Upgrades ROCHE HOLDING AG(RHHBY.US) to Buy Rating, Raises Target Price to $507.41
  Market Newswire · 2026/8/7
• Rating change
  TD Cowen Maintains ROCHE HOLDING AG(RHHBY.US) With Hold Rating, Maintains Target Price $67
  Market Newswire · 2026/2/11
• Rating change
  HSBC Maintains ROCHE HOLDING AG(RHHBY.US) With Buy Rating, Raises Target Price to $57
  Market Newswire · 2025/12/10
• Rating change
  HSBC Initiates ROCHE HOLDING AG(RHHBY.US) With Buy Rating, Announces Target Price $50
  Market Newswire · 2025/10/2
• Rating change
  The latest pharmaceutical industry rating by S&P reveals that Johnson & Johnson (JNJ.US) and Roche (RHHBY.US) are ranked at the top for superior financial and innovative abilities.
  Zhitong Finance · 2024/8/19
• Rating change
  Argus Research Initiates ROCHE HOLDING AG(RHHBY.US) With Buy Rating, Announces Target Price $55
  Market Newswire · 2026/4/6
• Rating change
  TD Cowen Maintains ROCHE HOLDING AG(RHHBY.US) With Hold Rating, Maintains Target Price $43
  Market Newswire · 2025/7/24
• Rating change
  Goldman Sachs Initiates ROCHE HOLDING AG(RHHBY.US) With Hold Rating
  Market Newswire · 2026/1/16
• The Center for Drug Evaluation (CDE) has accepted Roche's (RHHBY.US) marketing application for faricimab injection, indicated for the treatment of uveitic macular edema.
  Zhitong Finance · 2026/9/4
• Roche (RHHBY.US) submits BTK inhibitor for market approval
  Zhitong Finance · 2026/9/30
• Rating change
  Morgan Stanley Initiates ROCHE HOLDING AG(RHHBY.US) With Sell Rating, Announces Target Price $46
  Market Newswire · 2026/4/7
• Rating change
  Analysts Offer Insights on Healthcare Companies: SCHOTT Pharma AG & Co. KGaA (1SXP) and Roche Holding (RHHBY)
  TipRanks · 2025/12/6
• Rating change
  TD Cowen Maintains ROCHE HOLDING AG(RHHBY.US) With Hold Rating, Raises Target Price to $67
  Market Newswire · 2026/2/10
• Roche (RHHBY.US) reports positive mid-stage trial results for its weight-loss injection: average weight reduction of 15.5% over 48 weeks, with a 2.65% decrease in blood glucose indicators.
  Zhitong Finance · 2026/9/22
• Rating change
  Barclays Initiates ROCHE HOLDING AG(RHHBY.US) With Buy Rating
  Market Newswire · 2026/1/7
• Rating change
  Erste Group Initiates ROCHE HOLDING AG(RHHBY.US) With Hold Rating
  Market Newswire · 2024/11/5
• From treatment to prevention! Roche (RHHBY.US) initiates clinical trial of Brainshuttle therapy for Alzheimer's disease
  Zhitong Finance · 2026/7/15

Headlines are aggregated automatically and are not independently verified or edited by our team.